AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
188.28
-0.99 (-0.52%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close189.27
Open190.59
Bid187.05 x 100
Ask191.66 x 300
Day's Range187.06 - 192.01
52 Week Range182.80 - 256.80
Volume4,755,555
Avg. Volume2,812,842
Market Cap62.94B
Beta1.26
PE Ratio (TTM)5.74
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.80 (1.49%)
Ex-Dividend Date2017-08-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist3 days ago

    Allergan Stock: Performance in 3Q17

    Allergan stock has fallen ~15.4% in 3Q17. It has fallen 9.8% year-to-date as of October 20, 2017.

  • Barrons.com3 days ago

    Allergan: A Splitting Headache?

    Another analyst is weighing in on the growing guesswork regarding the likelihood that Allergan (AGN) could be heading for a break up. Allergan is appealing the decision, though the outcome of such a move is far from certain. Meanwhile, several analysts warn that a cheaper-priced generic version of Restasis could hit the U.S. market next year, eroding sales of Allergan’s second-biggest selling drug and creating a $1.5 billion revenue hole.

  • Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling
    Zacks3 days ago

    Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling

    Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.

  • Reuters3 days ago

    Imprimis Pharma to take on Allergan's Restasis with cheaper product

    San Diego-based Imprimis' therapy will cost 99 cents for a month's supply, with refills starting at $79 a month and the company will start selling prescriptions on Nov. 1, Imprimis' Chief Executive Mark Baum told Reuters. Allergan recently stirred controversy after striking a deal with the Native American Saint Regis Mohawk tribe that would shield certain patents on Restasis.

  • TheStreet.com4 days ago

    Allergan's Hard Fall Is Not Enough of a Reason to Buy

    AGN could make a capitulation low but it is a long way from making a bottom formation.

  • Barrons.com4 days ago

    Allergan: All In or Fall Out?

    Is Allergan (AGN) worth the risk? That’s the question analysts and investors are tackling this week after the drug maker got rocked by a federal court ruling that invalidated some of the patents protecting ...

  • Company News For Oct 19, 2017
    Zacks4 days ago

    Company News For Oct 19, 2017

    Companies in the News are: FOGO,ABT,AGN,EA

  • Conatus Entrusts Keith W. Marshall With Key Management Roles
    Zacks4 days ago

    Conatus Entrusts Keith W. Marshall With Key Management Roles

    Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

  • Barrons.com5 days ago

    The Biggest Loser: Allergan's Patent Troubles

    Allergan (AGN) fell to the bottom of the S&P 500 today as analysts predicted that the drug maker’s blockbuster eye drug Restasis could see a generic rival as soon as next year. Shares of Allergan fell more than 5.3% to close at $187.15 a share, on a day when the index edged 0.7% lower. On Monday, Allergan got rocked when a federal judge invalidated some of the patents protecting Restasis, opening the door for generic rivals that could push Allergan’s second-biggest selling drug off a cliff.

  • Why SUPERVALU, Synchronoss Technologies, and Allergan Slumped Today
    Motley Fool5 days ago

    Why SUPERVALU, Synchronoss Technologies, and Allergan Slumped Today

    Even as the market climbed, these stocks lagged behind. Find out why.

  • TheStreet.com5 days ago

    Allergan Shares Are Ready for a 30% Bounce Within Days

    Last October Allergan stock bounced off this support level; it could do it again.

  • Native American tribe holding patents sues Amazon and Microsoft
    Reuters5 days ago

    Native American tribe holding patents sues Amazon and Microsoft

    A Native American tribe sued Amazon.com Inc and Microsoft Corp in federal court in Virginia on Wednesday for infringing supercomputer patents it is holding for a technology firm. The Saint Regis Mohawk Tribe was assigned the patents by SRC Labs LLC in August, in a deal intended to use the tribe's sovereign status to shield them from administrative review. Microsoft and Amazon did not immediately return requests for comment.

  • Reuters5 days ago

    Native American tribe holding patents sues Amazon and Microsoft

    A Native American tribe sued Amazon.com Inc and Microsoft Corp in federal court in Virginia on Wednesday for infringing supercomputer patents it is holding for a technology firm. The Saint Regis Mohawk Tribe was assigned the patents by SRC Labs LLC in August, in a deal intended to use the tribe's sovereign status to shield them from administrative review.

  • CNBC5 days ago

    Mohawk tribe sues Microsoft, Amazon for patent infringement

    The tribe is a co-plaintiff with SRC Labs, which claims its data processing technology patents have been infringed for years.

  • Allergan ruling casts doubt on tribal patent strategy
    Reuters5 days ago

    Allergan ruling casts doubt on tribal patent strategy

    In a deal announced last month, Allergan transferred the Restasis patents to New York state's Saint Regis Mohawk Tribe, claiming the group's status as a sovereign nation meant the patents could not be reviewed by the U.S. patent office. Allergan said the move was justified because the same patents were already being reviewed in federal court, but critics said it was a cynical attempt to prolong the company's monopoly on Restasis.

  • Barrons.com5 days ago

    Is a Breakup Allergan's Best Bet?

    Is it too soon to talk about breaking up Allergan (AGN)? Bernstein analyst Aaron Gal met with Allergan CEO Brent Saunders yesterday following Monday’s ruling by a federal judge invalidating patents protecting the drug maker’s blockbuster dry-eye therapy Restasis. To be clear upfront, when asked, CEO Saunders noted that this is a "premature discussion" and it is his job to "think of everything," so him willing to comment does not suggest they are taking active steps in this direction.

  • TheStreet.com6 days ago

    Cramer: Getting Out the Bad News Gives a Post-Earnings Boost

    When management gets ahead of bad news, it allows a stock to prosper when the company reports earnings.

  • Reuters6 days ago

    Allergan ruling casts doubt on tribal patent strategy

    In a deal announced last month, Allergan transferred the Restasis patents to New York state's Saint Regis Mohawk Tribe, claiming the group's status as a sovereign nation meant the patents could not be reviewed by the U.S. patent office. Allergan said the move was justified because the same patents were already being reviewed in federal court, but critics said it was a cynical attempt to prolong the company's monopoly on Restasis.

  • Aerie (AERI) Up on FDA Review Committee Result for Rhopressa
    Zacks6 days ago

    Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

    Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.

  • Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall
    Zacks6 days ago

    Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall

    Allergan (AGN) lost a patent infringement lawsuit filed against companies trying to develop a generic version of its eye drug, Restasis, which is also its second bestselling drug.

  • How Allergan's 'Public Relations Backlash' Deepened This Week
    Investor's Business Daily6 days ago

    How Allergan's 'Public Relations Backlash' Deepened This Week

    Allergan already faced a "public relations backlash" after transferring the rights to its Restasis patents to a Native American tribe.

  • Barrons.com6 days ago

    And For Allergen's Next Trick..Filling a $1.5 Billion Hole?

    Not even Botox can wipe away the worry lines that followed Allergan’s (AGN) recent patent loss. Yesterday, a federal district court judge invalidated some of the patents protecting blockbuster dry-eye treatment Restasis, opening the door for generic rivals that could shove sales of Allergan’s second-biggest selling drug righ off a cliff. Many argue that the event is already baked into Allergan’s stock price, as is the public relations backlash from the controversial deal the drug maker struck last month with the Saint Regis Mohawk Tribe of upstate New York to block its Restasis patents from scrutiny by the U.S. Patent and Trade Office.

  • US cash equities are the best risk-adjusted rate return in town: NYSE trader
    Yahoo Finance Video3 days ago

    US cash equities are the best risk-adjusted rate return in town: NYSE trader

    Keith Bliss of Cuttone and Company joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the current rally in stocks and the importance of tax cuts.

  • Mohawk Tribe sues Microsoft, Amazon for patent infringeme...
    CNBC Videos5 days ago

    Mohawk Tribe sues Microsoft, Amazon for patent infringeme...

    CNBC's Meg Tirrell reports on the latest patent lawsuits from the Saint Regis Mohawk Tribe.

  • 4 health stocks and a gamer in the Blitz
    CNBC Videos5 days ago

    4 health stocks and a gamer in the Blitz

    Big movers in today's blitz